Novo Nordisk A/S $NVO Shares Bought by Prospera Financial Services Inc

Prospera Financial Services Inc boosted its position in shares of Novo Nordisk A/S (NYSE:NVO) by 11.3% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 420,795 shares of the company’s stock after buying an additional 42,789 shares during the period. Prospera Financial Services Inc’s holdings in Novo Nordisk A/S were worth $23,351,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also made changes to their positions in NVO. True Wealth Design LLC raised its stake in Novo Nordisk A/S by 209.8% in the 3rd quarter. True Wealth Design LLC now owns 443 shares of the company’s stock valued at $25,000 after purchasing an additional 300 shares during the last quarter. NewSquare Capital LLC raised its position in shares of Novo Nordisk A/S by 174.1% in the second quarter. NewSquare Capital LLC now owns 444 shares of the company’s stock valued at $31,000 after buying an additional 282 shares during the last quarter. Guerra Advisors Inc purchased a new position in shares of Novo Nordisk A/S in the third quarter worth about $25,000. Strengthening Families & Communities LLC acquired a new position in Novo Nordisk A/S during the third quarter worth about $30,000. Finally, Mid American Wealth Advisory Group Inc. purchased a new stake in Novo Nordisk A/S during the 2nd quarter valued at about $37,000. Hedge funds and other institutional investors own 11.54% of the company’s stock.

Novo Nordisk A/S Stock Up 3.6%

Shares of NYSE:NVO opened at $49.35 on Tuesday. The company has a market capitalization of $220.35 billion, a price-to-earnings ratio of 14.22 and a beta of 0.67. Novo Nordisk A/S has a 12-month low of $43.08 and a 12-month high of $93.80. The business has a 50-day moving average price of $53.63 and a 200 day moving average price of $53.58. The company has a current ratio of 0.80, a quick ratio of 0.57 and a debt-to-equity ratio of 0.61.

Novo Nordisk A/S (NYSE:NVO) last announced its quarterly earnings results on Tuesday, February 3rd. The company reported $1.01 earnings per share for the quarter, beating analysts’ consensus estimates of $0.90 by $0.11. Novo Nordisk A/S had a net margin of 33.03% and a return on equity of 68.91%. The business had revenue of $12.43 billion during the quarter, compared to analysts’ expectations of $11.97 billion. Sell-side analysts expect that Novo Nordisk A/S will post 3.84 EPS for the current year.

Novo Nordisk A/S Dividend Announcement

The company also recently declared a dividend, which will be paid on Wednesday, April 8th. Shareholders of record on Monday, March 30th will be paid a dividend of $1.2751 per share. This represents a yield of 541.0%. The ex-dividend date is Monday, March 30th. Novo Nordisk A/S’s dividend payout ratio is 23.63%.

Wall Street Analysts Forecast Growth

NVO has been the topic of a number of research reports. Zacks Research raised shares of Novo Nordisk A/S from a “strong sell” rating to a “hold” rating in a research note on Friday, January 9th. Citigroup initiated coverage on Novo Nordisk A/S in a research report on Tuesday, January 27th. They set a “neutral” rating on the stock. The Goldman Sachs Group restated a “buy” rating on shares of Novo Nordisk A/S in a report on Thursday, January 22nd. CICC Research started coverage on Novo Nordisk A/S in a report on Friday, January 9th. They set an “outperform” rating and a $73.50 price target on the stock. Finally, Argus reissued a “hold” rating on shares of Novo Nordisk A/S in a research report on Monday, December 8th. Seven investment analysts have rated the stock with a Buy rating, twelve have assigned a Hold rating and two have given a Sell rating to the company’s stock. Based on data from MarketBeat, Novo Nordisk A/S has an average rating of “Hold” and an average target price of $56.07.

Key Novo Nordisk A/S News

Here are the key news stories impacting Novo Nordisk A/S this week:

• Positive Sentiment: Novo forced a retreat by telehealth firm Hims & Hers: Hims pulled its $49 compounded semaglutide offering after legal threats and regulatory scrutiny, removing a near‑term, self‑pay price competitor to Wegovy. Article Title
• Positive Sentiment: Novo escalated with a patent‑infringement lawsuit vs Hims seeking to block compounded semaglutide sales — a legal step that should strengthen Novo’s intellectual‑property moat in the short to medium term. Article Title
• Positive Sentiment: Market reaction: Hims & Hers shares plunged on the regulatory/legal pushback, while Novo shares have bounced as investors view the threat to Wegovy/Ozempic economics as reduced. Article Title
• Positive Sentiment: Novo launched a share repurchase programme (part of a DKK 15bn plan) — a capital‑allocation move investors often view as supportive of the stock and EPS. Article Title
• Neutral Sentiment: Company & media pushback: Hims framed Novo’s lawsuit as aggressive PR; this dispute could draw out in court and media, creating short‑term volatility but an unclear long‑term impact. Article Title
• Negative Sentiment: Guidance shock: Novo sharply cut 2026 revenue and profit guidance, citing steep U.S. price declines and competition; the guidance revision triggered a prior ~25% one‑day drop and remains a key downside risk for near‑term earnings and valuation. Article Title
• Negative Sentiment: Regulatory headwind for Novo itself: The FDA sent a letter saying a Novo TV ad for the Wegovy pill contained “false or misleading” claims and requested corrective action — this raises reputational and marketing risks and could constrain U.S. promotional activity. Article Title

Novo Nordisk A/S Profile

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.